Integrated Wealth Concepts LLC Buys 4,526 Shares of Neurocrine Biosciences, Inc. $NBIX

Integrated Wealth Concepts LLC raised its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 167.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,233 shares of the company’s stock after buying an additional 4,526 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Neurocrine Biosciences were worth $800,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. Dodge & Cox grew its position in shares of Neurocrine Biosciences by 83.5% in the 1st quarter. Dodge & Cox now owns 5,534,624 shares of the company’s stock worth $612,129,000 after buying an additional 2,518,199 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Neurocrine Biosciences by 44.0% in the 1st quarter. Wellington Management Group LLP now owns 2,097,981 shares of the company’s stock worth $232,037,000 after buying an additional 640,556 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Neurocrine Biosciences by 3.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,539,601 shares of the company’s stock worth $170,281,000 after buying an additional 49,088 shares during the last quarter. Braidwell LP grew its position in shares of Neurocrine Biosciences by 32.2% in the 1st quarter. Braidwell LP now owns 1,191,925 shares of the company’s stock worth $131,827,000 after buying an additional 290,135 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Neurocrine Biosciences by 19.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,070,096 shares of the company’s stock worth $146,068,000 after buying an additional 175,879 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Insider Transactions at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 457 shares of the business’s stock in a transaction on Thursday, July 10th. The stock was sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the transaction, the insider owned 4,730 shares in the company, valued at $638,550. The trade was a 8.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kevin Charles Gorman sold 106,322 shares of the business’s stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $126.41, for a total value of $13,440,164.02. Following the completion of the transaction, the director owned 514,596 shares of the company’s stock, valued at $65,050,080.36. This represents a 17.12% decrease in their position. The disclosure for this sale can be found here. Insiders sold 186,960 shares of company stock worth $23,955,553 over the last quarter. 4.80% of the stock is currently owned by insiders.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $141.87 on Friday. The stock has a market capitalization of $14.07 billion, a PE ratio of 41.97, a price-to-earnings-growth ratio of 1.03 and a beta of 0.28. Neurocrine Biosciences, Inc. has a 52-week low of $84.23 and a 52-week high of $154.61. The company has a 50-day simple moving average of $134.13 and a two-hundred day simple moving average of $121.15.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, July 30th. The company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.08. The business had revenue of $687.50 million during the quarter, compared to analysts’ expectations of $653.09 million. Neurocrine Biosciences had a net margin of 13.88% and a return on equity of 13.22%. The business’s revenue for the quarter was up 16.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.63 earnings per share. As a group, equities research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NBIX has been the topic of a number of recent analyst reports. Morgan Stanley lifted their price objective on Neurocrine Biosciences from $158.00 to $163.00 and gave the stock an “overweight” rating in a research report on Friday, September 5th. UBS Group raised their target price on Neurocrine Biosciences from $152.00 to $174.00 and gave the company a “buy” rating in a research note on Wednesday, July 9th. Guggenheim raised their target price on Neurocrine Biosciences from $165.00 to $175.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Truist Financial assumed coverage on Neurocrine Biosciences in a research note on Monday, July 21st. They issued a “buy” rating and a $163.00 target price for the company. Finally, Wedbush raised their target price on Neurocrine Biosciences from $137.00 to $141.00 and gave the company an “outperform” rating in a research note on Thursday, July 31st. Eighteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $160.00.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.